Progressive stent technologies: new approaches for the treatment of cardiovascular diseases.
The CYPHER (Cordis, Johnson & Johnson) sirolimus-eluting stent and the TAXU (Boston Scientific) paclitaxel-eluting stent have been extensively evaluated and have been proven to be significant novel tools for the treatment of coronary artery disease. Several sirolimus derivatives have already emerged, receiving CE Mark approval. However, in the future, it is likely that drugs presently under investigation will address additional mechanisms associated with neointimal formation, either as single agents or in combination with antiproliferative compounds. Concurrently, alterations on stent platform design (helicoidal, open-closed cell), coatings (biodegradable, bioabsorbable, nanoporous) and polymers are being explored.
Vaina
Sophia
S
Thoraxcentre, Ba 583, Erasmus Medical Centre, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Serruys
Patrick W
PW
D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D000818:Animals; D002318:Cardiovascular Diseases / Q000628:therapy*; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000517:prevention & control; D004867:Equipment Design; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015607:Stents / Q000592:standards*
D020099:Coated Materials, Biocompatible; D017239:Paclitaxel; D020123:Sirolimus